Clinical trials
Gram-Negative Bacterial Infections clinical trials
Below are recruiting gram-negative bacterial infections clinical trials, each written for real people, not researchers. We’re tracking 14 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06907069Enrolling by invitationPhase 4
Combined treatment for drug-resistant bacteria in lung infections
This trial tests if giving a medication (colistin) both through an IV and as a mist you breathe in works better for lung infections caused by bacteria that are hard to treat with standard antibiotics. It may help patients who have these tough bacteria and are in the hospital.
Ningbo, ZAges 18–80 - NCT04291768RecruitingPhase 4
Shorter 5-day antibiotics for certain gram-negative bloodstream infections
This trial tests whether people with a specific type of bloodstream infection caused by gram-negative bacteria can safely take antibiotics for only 5 days instead of longer. It may help by reducing antibiotic exposure if your infection source is controlled quickly.
AalborgAges 18 years+ - NCT06135350RecruitingPhase 2
Preventing infections in ICU patients on ventilators
This trial tests an experimental drug called Fluorothiazinone to prevent serious bacterial infections in ICU patients who are on a breathing machine (ventilator) or likely to need one soon. It includes patients with COVID-19 pneumonia, stroke, or heart failure.
Moscow, MoscowAges 18 years+ - NCT06462235RecruitingPhase 2
Testing a new antibiotic for hospitalized babies with infection
This study tests a new antibiotic called aztreonam-avibactam (ATM-AVI) for treating serious bacterial infections in hospitalized babies under 9 months old. The goal is to see if it's safe and works well.
Orange, CaliforniaAges Up to 9 months - NCT07206745Recruiting
Chinese and Western medicine for severe pneumonia from drug-resistant bacteria
This trial tests a combination of traditional Chinese and Western medicine for adults with severe pneumonia caused by bacteria that are resistant to multiple antibiotics. It aims to see if this combined approach can improve treatment outcomes.
Zhengzhou, HenanAges 18–80 - NCT06966284Recruiting
Study Comparing Two Antibiotics for Resistant Infections
This study looks at two strong antibiotics, polymyxin B and colistin, given through a vein to treat serious infections like pneumonia or blood infections caused by bacteria that are resistant to many other antibiotics. The goal is to see how well they work and how safe they are.
TaipeiAges 18 years+ - NCT07004049RecruitingPhase 4
Testing combinations for resistant Gram-negative infections
This study tests different antibiotic combinations for severe infections caused by hard-to-treat Gram-negative bacteria (like Pseudomonas or Acinetobacter). The goal is to find the best treatment for bloodstream infections or pneumonia that started in the hospital.
Brisbane, QueenslandAges 18 years+ - NCT07063095RecruitingPhase 3
Testing two antibiotics combined for serious bacterial infections
This study tests whether combining two antibiotics (ceftazidime and fosfomycin) works better than ceftazidime alone for hospitalized adults with serious bacterial infections. If you have a severe infection thought to be caused by Gram-negative bacteria, this trial may offer a new treatment option.
Geneva, Canton of GenevaAges 18 years+ - NCT07086391Recruiting
Inhaled Polymyxin B for Resistant Pneumonia
This trial tests different ways of giving an inhaled antibiotic (polymyxin B) to people on a ventilator who have pneumonia caused by tough bacteria that don't respond to usual antibiotics. The goal is to find the best way to deliver the medicine to help clear the infection.
Fuzhou, FujianAges 18–90 - NCT05639647RecruitingPhase 2
Aztreonam plus avibactam for serious gram-negative infections
This trial compares two IV antibiotics (aztreonam and avibactam) against the best available treatment for serious gram-negative infections. It may help people who are hospitalized and need IV antibiotics, especially when the infection is caused by certain gram-negative bacteria.
San Diego, CaliforniaAges 9 months–17 years - NCT07478484RecruitingPhase 4
Different ways to take antibiotics for resistant infections
This trial tests two different schedules of a combination of antibiotics (ceftazidime-avibactam plus aztreonam) for people with serious infections caused by bacteria that are hard to treat. It aims to find the best way to give these medicines.
Nanjin, JiangsuAges 18–100 - NCT06602557RecruitingPhase 2
Inhaled antibiotic for lung infection during ECMO support
This trial tests whether adding an inhaled antibiotic (amikacin) to standard IV antibiotics can better treat a serious lung infection (pneumonia caused by Gram-negative bacteria) in patients on a heart-lung machine (ECMO) and a breathing tube. If you or your loved one is on ECMO and has this type of pneumonia, this study may offer a new treatment approach.
ParisAges 18 years+ - NCT05922124RecruitingPhase 4
Testing two antibiotics against resistant lung and bloodstream infections
This trial studies whether cefiderocol plus ampicillin-sulbactam works better than colistin (sometimes with meropenem) for serious infections caused by carbapenem-resistant Acinetobacter baumannii (a hard-to-treat germ). It may help by finding a more effective antibiotic plan for people with these severe hospital-acquired infections.
HaifaAges 16 years+ - NCT07326540RecruitingPhase 3
Testing a new antibiotic for drug-resistant pneumonia in the hospital
This trial compares a new antibiotic (BV100 plus low-dose polymyxin B) against a standard treatment for pneumonia caused by a hard-to-treat bacteria (Acinetobacter baumannii). If you have hospital-acquired or ventilator-associated pneumonia and standard antibiotics aren't working, this study may offer a new option.
TbilisiAges 18–82
Hear when a new Gram-Negative Bacterial Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for gram-negative bacterial infections?
- Yes. Clin2 currently lists 14 recruiting gram-negative bacterial infections studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a gram-negative bacterial infections trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a gram-negative bacterial infections trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.